Picard Medical

PMI

Market cap $164M

-Picard Medical / SynCardia Systems LLC mark historic milestone as a patient reaches 2,900 days of continuous support with the SynCardia Total Artificial Heart -- the longest timeframe in the world ever recorded-

TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5th through 6th, 2025 in Frankfurt, Germany.

TUCSON, Ariz., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it will present in vitro data on the fully implantable Emperor Total Artificial Heart (TAH) at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS 2025), held in Vienna, Austria from December 1st through 4th, 2025.

Significant milestone reached in advancing a driverless total artificial heart, strengthening Picard Medicals leadership in total artificial heart technology Significant milestone reached in advancing a driverless total artificial heart, strengthening Picard Medicals leadership in total artificial heart technology

– Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence – TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced financial results for the three and nine months ended September 30, 2025.

TUCSON, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will attend the Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum to be held on November 20, 2025, in New York, NY.

TUCSON, Ariz., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, today announced that it is not aware of any undisclosed material change in the Company's operations or financial condition, that would account for the recent volatility in its stock price.

- Patent portfolio secures innovation for the future of heart replacement - TUCSON, Ariz., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, today announced the strengthening of its intellectual property portfolio with the recent grant of U.S. Patent No.

TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, announced financial results for the quarter and six months ended June 30, 2025. In early September, Picard successfully closed its initial public offering, raising gross proceeds of $19.5 million.

Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership